drugset / Trial / NCT07545590
A Study of Eltrekibart (LY3041658) in Healthy Participants
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.
Timeline
- Start
- 2026-04-21
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrekibart | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.